COMBINATION THERAPY OF PD-1 TARGETED IL-2 VARIANT IMMUNOCYTOKINE AND ANTIBODY TO HUMAN PD-L1

Title:

COMBINATION THERAPY OF PD-1 TARGETED IL-2 VARIANT IMMUNOCYTOKINE AND ANTIBODY TO HUMAN PD-L1

Document Type and Number:

Japanese Patent JP2022045530

Kind Code:

A

Abstract:

To provide a novel therapy that can be added to an existing therapy in order to increase survival rate of a patient of advanced cancer.SOLUTION: A PD-1 targeted IL-2 variant immunocytokine having a specific sequence which is combined with an antibody that binds to human PD-L1 having a specific sequence, which is for use as a combination therapy of cancer treatment, a combination therapy of prevention or treatment of metastasis, or a combination therapy that stimulates an immune response or a function of T-cell activity or the like.SELECTED DRAWING: None

More Like This:

WO/2022/116952	ANTIGEN-BINDING PROTEIN TARGETING CD70 AND USE THEREOF
WO/2017/119521	NOVEL FUSION PROTEIN COMPRISING TRANSCRIPTION MODULATION DOMAIN OF P65 AND PROTEIN TRANSPORT DOMAIN AND USE THEREOF
WO/2022/171068	ENGINEERED CELLS AND USES THEREOF

Inventors:

STEPHANE ULSCHLAGER
DOUGLAS HANAHAN
LAURA CODARRI DEAK
CHRISTIAN KLEIN
VALERIA NICOLINI
PABLO UMANIA

Application Number:

JP2020151170A

Publication Date:

March 22, 2022

Filing Date:

September 09, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

HOFFMANN LA ROCHE

International Classes:

C07K19/00; A61K35/17; A61K38/19; A61K38/20; A61K39/00; A61K39/395; A61P35/00; A61P35/02; A61P35/04; A61P43/00

Attorney, Agent or Firm:

Sonoda/Kobayashi Patent Business Corporation

Previous Patent: Information processing equipment, system, control method of information processing equipment

Next Patent: Control method of liquid injection device and liquid injection device